Swedish firm in Chinese HIV deal
Swedish biotech company Medivir has licensed development of its HIV drug MIV-160 to Chinese company Guangdong Lantai Viewland Pharmaceuticals.
Under the deal, the Chinese company will take charge of development of the drug and commercialization in China, Hong Kong, Macao and Taiwan.
Medivir will be paid in the form of shares in the Chinese company, and will also receive royalty payments on sales.
The drug, a non-nucleaoside HIV reverse transcriptase inhibitor, is in late pre-clinical development. Medivir says the drug can provide a chemical barrier to prevent HIV transmission, as well as being used to treat the condition.
Zho Hai-Feng, chairman of Guangdong Lantai Viewland Pharmaceuticals, said the deal with Medivir was a milestone for HIV prevention and treatment in China.
"I believe that the development of an effective prevention method is a vital element to keep this virus in check, and MIV-160 offers a valuable opportunity," he said.
Comments
See Also
Under the deal, the Chinese company will take charge of development of the drug and commercialization in China, Hong Kong, Macao and Taiwan.
Medivir will be paid in the form of shares in the Chinese company, and will also receive royalty payments on sales.
The drug, a non-nucleaoside HIV reverse transcriptase inhibitor, is in late pre-clinical development. Medivir says the drug can provide a chemical barrier to prevent HIV transmission, as well as being used to treat the condition.
Zho Hai-Feng, chairman of Guangdong Lantai Viewland Pharmaceuticals, said the deal with Medivir was a milestone for HIV prevention and treatment in China.
"I believe that the development of an effective prevention method is a vital element to keep this virus in check, and MIV-160 offers a valuable opportunity," he said.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.